Yıl: 2021 Cilt: 54 Sayı: 3 Sayfa Aralığı: 281 - 290 Metin Dili: Türkçe DOI: 10.5505/aot.2021.26576 İndeks Tarihi: 24-05-2022

Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer

Öz:
Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and later line setting. Herein we aimed to evaluate the efficacy and safety of immunotherapy for the second and later line settings in metastatic NSCLC patients as a single center experience. Methods: Totally, 37 patients with metastatic NSCLC who received atezolizumab or nivolumab in the second or later lines were included. Clinicopathological features of patients and survival outcomes were analyzed. The safety profile and the factors that may predict survival were also evaluated. Results: Twenty-nine (78.4%) of patients were men and 8 of patients (21.6%) were woman with median age of 61 years (range:42-80). Atezolizumab was preferred in 22 (59.5%) of these patients and nivolumab in 15 (40.5%) of them. Objective response rate was 35.1%. At a median follow up of 22.5 months, median progression-free survival (PFS) was 4.7 months, median overall survival (OS) was 24.1 months. Univariate analysis for PFS revealed that gender (p=0.03), age (p=0.005), the presence of brain metastasis (p=0.02), PDL-1 status >1% (p=0.035), ECOG PS (p=0.04) and the good response to frontline treatment (p=0.015) were found to be significant prognostic indicators. It also showed that the presence of brain metastasis (p=0.03), PDL-1 status >1% (p=0.027), good response to frontline treatment (p=0.022) and atezolizumab preference (p=0.018) were prognostic factors for OS. Conclusion: Our real-life analysis indicated that atezolizumab and nivolumab improved survivals with good safety profile in second and later lines treatment of metastatic NSCLC patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
1
0
  • 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statisti cs, 2021. CA Cancer J Clin 2021; 71:7.
  • 2. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020; 383:640.
  • 3. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998.
  • 4. Nivolumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata. fda.gov/ drugsatfda_docs/label/2020/125554s082lbl.pdf (Accessed on May 27, 2020).
  • 5. Atezolizumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata. fda.gov/ drugsatfda_docs/label/2020/761034s027lbl.pdf (Accessed on June 02, 2020).
  • 6. Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov /drugsatfda_docs/label/2020/125514s059s064s 076s083lbl.pdf (Accessed on April 29, 2020).
  • 7. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:123.
  • 8. Horn L, Spigel DR, Vokes EE, et al. Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes from Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017; 35:3924.
  • 9. Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 2018; 29:959.
  • 10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:1627.
  • 11. Horn L, Brahmer J, Reck M, et al. Phase 3, randomized trial (CheckMate 057) of nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer: Subgroup analyses and patient-reported outcomes. Ann Oncol 2015; 26S: ESMO #4170.
  • 12. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389:255.
  • 13. Fehrenbacher L, von Pawel J, Park K, et al. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non- Small Cell Lung Cancer. J Thorac Oncol 2018; 13:1156.
  • 14. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PDL-1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387:1540.
  • 15. Herbst RS, Garon EB, Kim DW, et al. Long- Term Outcomes and Retreatment Among Patients with Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small- Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol 2020; 38:1580.
  • 16. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PDL-1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375. 17. Nasser NJ, Gorenberg M, Agbarya A. et al. First line Immunotherapy for Non-Small Cell Lung Cancer Pharmaceuticals (Basel). 2020 Nov 8; 13(11): 373.
  • 18. Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes from the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non- Small-Cell Lung Cancer. J Clin Oncol 2021; 39:723.
  • 19. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients with Advanced Non‒Small-Cell Lung Cancer Treated with Pembrolizumab: Results from the Phase I KEYNOTE-001 Study. J Clin Oncol 2019; 37:2518.
  • 20. Janzic U, Kern I, Janzic A, Cavka L, Cufer T. PDL-1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. Radiol. Oncol. 2017; 51(3), 357–362.
  • 21. Rizvi NA, Hellmann MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348, 124–128.
  • 22. Herbst RS, Soria JC, Kowanetz M. et al Predictive correlates of response to the anti-PDL- 1 antibody MPDL3280A in cancer patients. Nature. 2014;515 (7528): 563-7.
  • 23. Karak FE, Haddad FG, Eid R et al Lung cancer and immunotherapy: a real-life experience from second line and beyond Future Oncol. 2019; 15(26): 3025-3032.
APA Göktaş Aydın S, acikgoz o, KUTLU Y, BILICI A, HAMDARD J, ÖLMEZ Ö, yildiz o (2021). Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. , 281 - 290. 10.5505/aot.2021.26576
Chicago Göktaş Aydın Sabin,acikgoz ozgur,KUTLU Yasin,BILICI AHMET,HAMDARD Jamshid,ÖLMEZ Ömer Fatih,yildiz ozcan Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. (2021): 281 - 290. 10.5505/aot.2021.26576
MLA Göktaş Aydın Sabin,acikgoz ozgur,KUTLU Yasin,BILICI AHMET,HAMDARD Jamshid,ÖLMEZ Ömer Fatih,yildiz ozcan Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. , 2021, ss.281 - 290. 10.5505/aot.2021.26576
AMA Göktaş Aydın S,acikgoz o,KUTLU Y,BILICI A,HAMDARD J,ÖLMEZ Ö,yildiz o Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. . 2021; 281 - 290. 10.5505/aot.2021.26576
Vancouver Göktaş Aydın S,acikgoz o,KUTLU Y,BILICI A,HAMDARD J,ÖLMEZ Ö,yildiz o Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. . 2021; 281 - 290. 10.5505/aot.2021.26576
IEEE Göktaş Aydın S,acikgoz o,KUTLU Y,BILICI A,HAMDARD J,ÖLMEZ Ö,yildiz o "Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer." , ss.281 - 290, 2021. 10.5505/aot.2021.26576
ISNAD Göktaş Aydın, Sabin vd. "Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer". (2021), 281-290. https://doi.org/10.5505/aot.2021.26576
APA Göktaş Aydın S, acikgoz o, KUTLU Y, BILICI A, HAMDARD J, ÖLMEZ Ö, yildiz o (2021). Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. ACTA ONCOLOGICA TURCICA, 54(3), 281 - 290. 10.5505/aot.2021.26576
Chicago Göktaş Aydın Sabin,acikgoz ozgur,KUTLU Yasin,BILICI AHMET,HAMDARD Jamshid,ÖLMEZ Ömer Fatih,yildiz ozcan Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. ACTA ONCOLOGICA TURCICA 54, no.3 (2021): 281 - 290. 10.5505/aot.2021.26576
MLA Göktaş Aydın Sabin,acikgoz ozgur,KUTLU Yasin,BILICI AHMET,HAMDARD Jamshid,ÖLMEZ Ömer Fatih,yildiz ozcan Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. ACTA ONCOLOGICA TURCICA, vol.54, no.3, 2021, ss.281 - 290. 10.5505/aot.2021.26576
AMA Göktaş Aydın S,acikgoz o,KUTLU Y,BILICI A,HAMDARD J,ÖLMEZ Ö,yildiz o Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. ACTA ONCOLOGICA TURCICA. 2021; 54(3): 281 - 290. 10.5505/aot.2021.26576
Vancouver Göktaş Aydın S,acikgoz o,KUTLU Y,BILICI A,HAMDARD J,ÖLMEZ Ö,yildiz o Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer. ACTA ONCOLOGICA TURCICA. 2021; 54(3): 281 - 290. 10.5505/aot.2021.26576
IEEE Göktaş Aydın S,acikgoz o,KUTLU Y,BILICI A,HAMDARD J,ÖLMEZ Ö,yildiz o "Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer." ACTA ONCOLOGICA TURCICA, 54, ss.281 - 290, 2021. 10.5505/aot.2021.26576
ISNAD Göktaş Aydın, Sabin vd. "Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer". ACTA ONCOLOGICA TURCICA 54/3 (2021), 281-290. https://doi.org/10.5505/aot.2021.26576